| The translation of cell-based therapies: clinical landscape and manufacturing challenges TRJ Heathman, AW Nienow, MJ McCall, K Coopman, B Kara, CJ Hewitt Regenerative medicine 10 (1), 49-64, 2015 | 332 | 2015 |
| Systems and devices to identify and limit nerve conduction BH Mehta, M McCall, SA McGill US Patent 9,693,817, 2017 | 59 | 2017 |
| The global cell therapy industry continues to rise during the second and third quarters of 2012 C Mason, MJ McCall, EJ Culme-Seymour, S Suthasan, S Edwards-Parton, ... Cell stem cell 11 (6), 735-739, 2012 | 36 | 2012 |
| The productivity limit of manufacturing blood cell therapy in scalable stirred bioreactors R Bayley, F Ahmed, K Glen, M McCall, A Stacey, R Thomas Journal of tissue engineering and regenerative medicine 12 (1), e368-e378, 2018 | 35 | 2018 |
| Systems and devices to identify and limit nerve conduction BH Mehta, M McCall, SA McGill US Patent 9,113,912, 2015 | 30 | 2015 |
| Comparability: manufacturing, characterization and controls, report of a UK regenerative medicine platform pluripotent stem cell platform workshop, trinity hall, cambridge, 14 … DJ Williams, R Archer, P Archibald, I Bantounas, R Baptista, R Barker, ... Regenerative medicine 11 (5), 483-492, 2016 | 28 | 2016 |
| Stem cell culture conditions and stability: a joint workshop of the PluriMes Consortium and Pluripotent Stem Cell Platform GN Stacey, PW Andrews, I Barbaric, C Boiers, A Chandra, G Cossu, ... Regenerative medicine 14 (3), 243-255, 2019 | 21 | 2019 |
| Qualification of academic facilities for small-scale automated manufacture of autologous cell-based products P Hourd, A Chandra, D Alvey, P Ginty, M McCall, E Ratcliffe, E Rayment, ... Regenerative medicine 9 (6), 799-815, 2014 | 19 | 2014 |
| Cell Culture System M McCall, R Thomas US Patent App. 15/036,948, 2016 | 12 | 2016 |
| Distributed automated manufacturing of pluripotent stem cell products M Shariatzadeh, A Chandra, SL Wilson, MJ McCall, L Morizur, L Lesueur, ... The International Journal of Advanced Manufacturing Technology 106, 1085-1103, 2020 | 10 | 2020 |
| Developing Cell Therapies: Enabling cost prediction by value systems modeling to manage developmental risk. MJ McCall, DJ Williams Journal of Commercial Biotechnology 19 (2), 2013 | 8 | 2013 |
| From protocol to product: ventral midbrain dopaminergic neuron differentiation for the treatment of Parkinson's disease JWT Kusena, RJ Thomas, MJ McCall, SL Wilson Regenerative Medicine 14 (11), 1057-1069, 2019 | 4 | 2019 |
| FOLLOW-UP OF COMPLEX VENTRICULAR ARRHYTHMIAS IN HEALTHY-YOUNG ADULTS AND CHILDREN JB Gordon, LC Evans, GH Beckwith, MM McCall, RJ Simpson, JR Foster CLINICAL RESEARCH 27 (2), A170-A170, 1979 | 4 | 1979 |
| A new automated vial thawer controls the thawing of cryopreserved mesenchymal stem cells to achieve high cell viability and growth potential P Mitchell, E Cheeseman, J Harriman, KE Glen, M McCall, R Thomas Cytotherapy 19 (5), S121-S122, 2017 | 2 | 2017 |
| Cell therapy distributed manufacturing, man-aging costs and risks MJ McCall, DJ Williams Cytotherapy 15 (4), S51, 2013 | 2 | 2013 |
| Translational requirements for enhanced characterisation of manufactured dopaminergic neurons for the treatment of Parkinson's disease J Kusena, S Wilson, R Thomas, M McCall Cytotherapy 20 (5), S66-S67, 2018 | 1 | 2018 |
| Systems and devices to identify and limit nerve conduction BH Mehta, M McCall, SA McGill US Patent App. 15/608,757, 2017 | 1 | 2017 |
| Application of quality by design tools to upstream processing of platelet precursor cells to enable in vitro manufacture of blood products EA Cheeseman, KE Glen, A Stacey, JC Beltran-Rendon, RLL Moore, ... | | 2019 |
| First steps towards understanding cell losses in downstream processing W Mitchell, R Thomas, M McCall Cytotherapy 20 (5), S68, 2018 | | 2018 |
| Quality approaches to allow multi-site equivalence in pluripotent stem cell based product manufacturing M Shariatzadeh, S Wilson, A Chandra, S Sebastian, M McCall, R Thomas, ... Loughborough University, 2017 | | 2017 |
